DATAMEDS AI, INC.

NASDAQ: MEDS (DataMeds AI, Inc.)

最近更新时间: 4天之前, 3:13AM

0.640

0.00 (-0.28%)

前收盘价格 0.642
成交量 551,574
价格/销量 (P/S) 0.240
52周波幅
0.493 (-23%) — 33.15 (5077%)
营业毛利率 52.46%
营业利益率 (TTM) -153.67%
稀释每股收益 (EPS TTM) -24.38
总债务/股东权益 (D/E MRQ) 1.48%
流动比率 (MRQ) 4.75
资产报酬率 (ROA TTM) -71.92%
股东权益报酬率 (ROE TTM) -269.31%

AIStockmoo 评分

-2.1
负债低。盈利能力弱。短期流动性充足。 参考
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
资本回报 参考 NA
盈利趋势 参考 NA
持仓估值 参考 NA
风险溢价 参考 NA
市场估值 参考 NA
过去一年呈下降趋势。股价远低于52周高点。 参考
下降趋势:股价位于均线之下,均线向下。股价已大幅低于均线。下跌日成交量较大。 参考
来自我们对走势图的 AI 技术分析。 参考 NA
K线形态 参考 NA
近期没有目标价,因此依据目标价的调整方向。 参考
持仓情绪 参考 NA
新闻情绪 参考 NA
机构在最新13F申报中净+0.66%的股份:10家增持,4家减持(截至30 Sep 2026的季度)。 参考
空头持仓从31 Aug到30 Oct 2026变化+113.5%,回补天数1天(FINRA)。 参考
内部交易活动 参考 NA
市场环境偏谨慎。 参考
行业表现落后大市。
各支柱方向一致,评分因此加强。
低于中期趋势线。 参考
股价低于其52周平均水平。5年来下跌。 参考
短、中、长期趋势均向下。短期动能下降。 参考
支撑与阻力水平趋升。 参考
最终评分 -2.09
全部展开

市场趋势

短期 中期
行业 Pharmaceutical Retailers (US) 混合的 混合的
Pharmaceutical Retailers (全球的) 混合的 混合的
股票 DataMeds AI, Inc. 混合的 混合的

相关股票

股票 市值 DY P/E(TTM) P/B 评分
MEDS - - - - -2.1
WBA 10 B 4.34% - 1.44 -2.0
PETS 19 M - - 1.18 -3.9
RDGT 853 K - - 0.020 -2.2
SCNX - - - 0.080 -1.6
HITI 199 M - - 2.95 -1.7

Trxade Health Inc is a health service IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey, and patient engagement in the U.S. Its products and services include Integra Pharma Solutions, LLC, Community Specialty Pharmacy, LLC, Delivmeds.com, Bonum Health Hub and Application, and others. its business is classified into reportable segments which are Trxade, Inc, Superlatus, LLC, Integra Pharma, LLC, and Other, and the majority of the revenue comes from Trxade, Inc.

部门 Healthcare
行业 Pharmaceutical Retailers
投资方式 Small Value
内部持股比例 63.99%
机构持股比例 10.25%

所有权

姓名 日期 持有股份
Onedigital Investment Advisors Llc 30 Sep 2026 21,369

该时间范围内无数据。

该时间范围内无数据。

机构

机构持股比例: 1.62%

持仓变动 机构数 股数
增持 10 49,514
减持 4 23,584
新建仓 7 34,444
清仓 1 20,532

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 371,417 1.0
15 Oct 2026 476,294 1.0
30 Sep 2026 525,081 1.0
15 Sep 2026 430,628 1.0
31 Aug 2026 173,986 1.0
14 Aug 2026 164,850 1.0

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

2 正面 0 负面 0 中性
日期 类型 细节
05 Nov 2026 Yahoo Finance DataMeds AI Signs Preliminary Agreement With Florida Health Insurer for GLP-1 Patient Management App
DataMeds AI, Inc. (NASDAQ:MEDS) announced that it has entered into a non-binding memorandum of understanding (MOU) with a Florida-based health maintenance organization (HMO) to introduce its Health Lives Here mobile application to the insurer’s members, initially focusing on patients receiving…
02 Nov 2026 Yahoo Finance DataMEDS AI Secures Supply Agreement for Six Compounded Peptides Following FDA Advisory Committee Recommendations
DataMEDS AI, Inc. (NASDAQ:MEDS) has announced that its pharmacy subsidiary, Corexa Health, has entered into a commercial supply agreement covering bulk drug substances and active pharmaceutical ingredients (APIs) for six peptides, as the company prepares to expand its compounded prescription…
23 Oct 2026 Yahoo Finance DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
The aim of HLH CRP is to bring respiratory season best practices to community pharmacies and improve access to protein-based vaccines, diagnostics and therapeutics targeting respiratory infectious diseases as cold and flu season begins across the U. Corexa Pharmacy in Lakeland, Florida will be the…
20 Oct 2026 Yahoo Finance DataMeds Regains Compliance With NASDAQ Listing Standards
TAMPA, FL / ACCESS Newswire / October 20, 2026 / DataMeds AI, Inc. In order to regain compliance with the Equity Rule, DataMEDS needed to have a minimum stockholders' equity of $2…
16 Oct 2026 Yahoo Finance DataMeds AI Plans Peptide Compounding Expansion Through Corexa Health Following FDA Policy Proposal
DataMeds AI, Inc. (NASDAQ:MEDS) has outlined plans to expand into the peptide compounding market through its pharmacy subsidiary, Corexa Health, following a proposed policy change by the U.
16 Oct 2026 Yahoo Finance DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
Corexa Health's three divisions - pharmacy, distribution, and tech & hub - positioned to serve the emerging compounded peptide marketTAMPA, FL / ACCESS Newswire / October 16, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company…
14 Oct 2026 Yahoo Finance DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
Platform to be integrated into Health Lives Here app as a subscription offeringTAMPA, FL / ACCESS Newswire / October 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure…
13 Oct 2026 Yahoo Finance DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers TAMPA, FL – DataMeds AI, Inc. (NASDAQ:MEDS) (“DataMeds AI,” “DataMEDS SI,” “DataMEDS,” or the “Company”), a…
13 Oct 2026 Yahoo Finance DataMeds AI Announces Workforce Reductions as It Prioritises ChemoFx Cancer Diagnostic Test Commercialisation
DataMeds AI, Inc. (NASDAQ:MEDS) has announced cost-reduction measures, including cuts to corporate management positions, as the company redirects resources towards commercialising its ChemoFx diagnostic laboratory test for gynaecological cancers.
12 Oct 2026 Yahoo Finance DataMeds AI Secures Medicaid Coverage for ChemoFx Assay in Gynecologic Cancers
DataMeds AI’s Helomics subsidiary has received a Medicaid coverage determination under Humana’s policy, potentially expanding reimbursement access for its precision oncology test while supporting commercial growth. Key Investor TakeawaysDataMeds AI (NASDAQ:MEDS) has secured a Medicaid coverage…
12 Oct 2026 Yahoo Finance DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
Humana adds ChemoFx® to its Medicaid Pharmacogenomics Testing coverage policyTAMPA, FL / ACCESS Newswire / October 12, 2026 / DataMeds AI, Inc. Medical Coverage Policies were reviewed by Humana's Medicaid Coverage Policy Adoption (MCPA) Forum, which incorporated the ChemoFx Assay in its Coverage…
01 Oct 2026 Yahoo Finance DataMeds AI Corexa Pharmacy Surpasses $1 Million in Monthly Revenue as Sales Rise 66%
Corexa Pharmacy’s preliminary September revenue increased more than 66% from July, supported by retail customer growth and the launch of Tollo Health products. Key Investor TakeawaysDataMeds AI (NASDAQ:MEDS) said Corexa Pharmacy generated preliminary, unaudited September 2026 revenue of more than…
01 Oct 2026 Yahoo Finance DataMeds AI's Corexa Pharmacy Surpasses $1 Million In Monthly Revenue
September 2026 revenue up more than 66 percent from July 2026 with expansion of retail customer base and Tollo Health pharmaceutical-adjunct product launchesTAMPA, FL / ACCESS Newswire / October 1, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare…
28 Sep 2026 Yahoo Finance Axe Compute Just Sold Its Cancer Business to Become an AI Stock
Axe Compute stock has rallied over 650% in the past six months as investors increasingly value it as an AI infrastructure stock. The challenge is now delivering on that promise.
28 Sep 2026 Yahoo Finance DataMeds AI Launches Health Lives Here App Focused on GLP-1 Telehealth and Pharmacy Services
DataMeds AI (NASDAQ:MEDS) and Tollo Health launched the Health Lives Here mobile application, combining GLP-1 telehealth, pharmacy services, nutritional products and health tracking as part of a planned broader healthcare network. Key Investor TakeawaysDataMeds AI (NASDAQ:MEDS) and Tollo Health…
28 Sep 2026 Yahoo Finance DataMeds AI stock rises on health app launch
Investing.com -- DataMeds AI Inc (NASDAQ:MEDS) shares jumped 25% Monday following the launch of its Health Lives Here mobile application in partnership with Tollo Health.
28 Sep 2026 Yahoo Finance DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application
Healthcare IT Company and Nutritional Products Maker to Work with NFL Alumni Health to Drive Awareness of GLP-1 Telehealth and Pharmacy ServicesTAMPA, FL / ACCESS Newswire / September 28, 2026 / DataMeds AI, Inc. The companies intend to expand the target patient populations in the fourth quarter of…
25 Sep 2026 Yahoo Finance DataMEDS AI To Present At 2026 National Telehealth and Virtual Care Summit
Interim Co-CEO to Discuss Growing Patient Desire to Own Health DataTAMPA, FL / ACCESS Newswire / September 25, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial…
显示更多
除息日 公告日期 支付日期 详情
19 Jul 2024 08 Jul 2024 24 Jul 2024 1.5 现金
25 Mar 2024 28 Feb 2024 22 Mar 2024 8 现金

技术形态 中期

趋势排列
斜率
入场位置
成交量
下降趋势:股价位于均线之下,均线向下。股价已大幅低于均线。下跌日成交量较大。
最近阻力: 0.740 – 0.933 · 强

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

风险 / 回报
TP1:
TP2:

以入场价计算,止损的亏损相对每个目标价的盈利。通常追求 2 或以上的比率。

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票